PATIENT NAME: NEHA GUPTA REF. DOCTOR: SELF CODE/NAME & ADDRESS: C000138394 AGE/SEX

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHÍ

NEW DELHI 110030 8800465156

ACCESSION NO: 0181WD000456

PATIENT ID : NEHAF091291181

CLIENT PATIENT ID: ABHA NO

:31 Years

Female

DRAWN

RECEIVED : 08/04/2023 08:15:06 REPORTED :12/04/2023 14:48:38

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

XRAY-CHEST

NO ABNORMALITY DETECTED **IMPRESSION**

TMT OR ECHO

TMT OR ECHO **NEGATIVE**

ECG

ECG WITHIN NORMAL LIMITS

MEDICAL HISTORY

NOT SIGNIFICANT RELEVANT PRESENT HISTORY RELEVANT PAST HISTORY NOT SIGNIFICANT

RELEVANT PERSONAL HISTORY MARRIED / 1 CHILD / VEG DIET / NO ALLERGIES / NO SMOKING / NO

ALCOHOL.

MENSTRUAL HISTORY (FOR FEMALES) LACTATIONAL AMENORRHEA.

LMP (FOR FEMALES) 26/5/2022. OBSTETRIC HISTORY (FOR FEMALES) 1FTNDA0L1 LCB (FOR FEMALES) 2 MONTH BACK. NOT SIGNIFICANT RELEVANT FAMILY HISTORY NOT SIGNIFICANT OCCUPATIONAL HISTORY NOT SIGNIFICANT HISTORY OF MEDICATIONS

ANTHROPOMETRIC DATA & BMI

HEIGHT IN METERS 1.57 mts WEIGHT IN KGS. 71 Kgs

BMI BMI & Weight Status as follows/sqmts 29

> Below 18.5: Underweight 18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese

GENERAL EXAMINATION

MENTAL / EMOTIONAL STATE NORMAL PHYSICAL ATTITUDE NORMAL GENERAL APPEARANCE / NUTRITIONAL **OVERWEIGHT**

STATUS

AVERAGE BUILT / SKELETAL FRAMEWORK NORMAL FACIAL APPEARANCE

Page 1 Of 20





Tel: 9111591115, Fax: CIN-U74899PB1995PLC045956

Email: customercare.thane@srl.in



PATIENT NAME: NEHA GUPTA REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000138394 ACCESSION NO: 0181WD000456 AGE/SEX

CODE/NAME & ADDRESS : C000138394 ACCESSION NO : 0181W D000456 AGE/SEX : 31 Years Female
ACROFEMI HEALTHCARE LTD (MEDIWHEEL) PATIENT ID : NEHAF091291181 DRAWN :

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI

NEW DELHI 110030 8800465156
 CLIENT PATIENT ID:
 RECEIVED: 08/04/2023 08:15:06

 ABHA NO:
 REPORTED: 12/04/2023 14:48:38

Test Report Status <u>Final</u> Results Biological Reference Interval Units

SKIN NORMAL
UPPER LIMB NORMAL
LOWER LIMB NORMAL
NECK NORMAL

NECK LYMPHATICS / SALIVARY GLANDS NOT ENLARGED OR TENDER

THYROID GLAND NOT ENLARGED

CAROTID PULSATION NORMAL BREAST (FOR FEMALES) NORMAL TEMPERATURE NORMAL

PULSE 88/MIN.REGULAR, ALL PERIPHERAL PULSES WELL FELT, NO CAROTID

BRUIT

RESPIRATORY RATE NORMAL

CARDIOVASCULAR SYSTEM

BP 114/80 MM HG mm/Hg

NOT PALPABLE

(SUPINE)

PERICARDIUM NORMAL
APEX BEAT NORMAL
HEART SOUNDS NORMAL
MURMURS ABSENT

RESPIRATORY SYSTEM

SIZE AND SHAPE OF CHEST NORMAL
MOVEMENTS OF CHEST SYMMETRICAL
BREATH SOUNDS INTENSITY NORMAL

BREATH SOUNDS QUALITY VESICULAR (NORMAL)

ADDED SOUNDS ABSENT

PER ABDOMEN

SPLEEN

APPEARANCE NORMAL
VENOUS PROMINENCE ABSENT
LIVER NOT PALPABLE

HERNIA ABSENT

CENTRAL NERVOUS SYSTEM

HIGHER FUNCTIONS NORMAL

Page 2 Of 20





View Details

Now Deser

Tel: 9111591115, Fax: CIN-U74899PB1995PLC045956

Email: customercare.thane@srl.in



PATIENT NAME: NEHA GUPTA REF. DOCTOR: SELF CODE/NAME & ADDRESS: C000138394 ACCESSION NO: 0181WD000456 AGE/SEX :31 Years Female ACROFEMI HEALTHCARE LTD (MEDIWHEEL) PATIENT ID DRAWN : NEHAF091291181 F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 08/04/2023 08:15:06 DELHÍ ABHA NO REPORTED :12/04/2023 14:48:38 **NEW DELHI 110030** 8800465156

Test Report Status Final Results Biological Reference Interval Units

CRANIAL NERVES NORMAL

CEREBELLAR FUNCTIONS NORMAL

CEREBELLAR FUNCTIONS NORMAL NORMAL SENSORY SYSTEM MOTOR SYSTEM NORMAL REFLEXES NORMAL MUSCULOSKELETAL SYSTEM SPINE NORMAL **JOINTS** NORMAL **BASIC EYE EXAMINATION** CONJUNCTIVA **NORMAL EYELIDS NORMAL** EYE MOVEMENTS NORMAL **CORNEA** NORMAL DISTANT VISION RIGHT EYE WITHOUT WITHIN NORMAL LIMIT GLASSES WITHIN NORMAL LIMIT DISTANT VISION LEFT EYE WITHOUT **GLASSES** NEAR VISION RIGHT EYE WITHOUT GLASSES WITHIN NORMAL LIMIT WITHIN NORMAL LIMIT NEAR VISION LEFT EYE WITHOUT GLASSES NORMAL COLOUR VISION SUMMARY

REMARKS / RECOMMENDATIONS ANNUAL HEALTH CHECK UP.

NOT SIGNIFICANT

OVERWEIGHT.

Page 3 Of 20





View Details

View Repor

RELEVANT HISTORY

RELEVANT GP EXAMINATION FINDINGS



PATIENT NAME: NEHA GUPTA REF. DOCTOR: SELF CODE/NAME & ADDRESS : C000138394 ACCESSION NO: 0181WD000456 AGE/SEX :31 Years Female ACROFEMI HEALTHCARE LTD (MEDIWHEEL) PATIENT ID DRAWN : NEHAF091291181 F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 08/04/2023 08:15:06 DELHÍ ABHA NO REPORTED :12/04/2023 14:48:38 **NEW DELHI 110030** 8800465156

Biological Reference Interval Test Report Status Results Units <u>Final</u>

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

ULTRASOUND ABDOMEN

ULTRASOUND ABDOMEN

NO ABNORMALITIES DETECTED

Interpretation(s)

THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL

EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.

End Of Report Please visit www.srlworld.com for related Test Information for this accession

Page 4 Of 20







SRL Ltd S.K. Tower, Hari Niwas, LBS Marg THANE, 400602 MAHARASHTRA, INDIA Tel: 9111591115, Fax: CIN-U74899PB1995PLC045956 Email: customercare.thane@srl.in



REF. DOCTOR: SELF **PATIENT NAME: NEHA GUPTA** CODE/NAME & ADDRESS: C000138394 ACCESSION NO: 0181WD000456 AGE/SEX :31 Years Female ACROFEMI HEALTHCARE LTD (MEDIWHEEL) DRAWN PATIENT ID : NEHAF091291181 F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST RECEIVED : 08/04/2023 08:15:06 CLIENT PATIENT ID: DELHI REPORTED :12/04/2023 14:48:38 ABHA NO **NEW DELHI 110030** 8800465156

Test Report Status Final Results Biological Reference Interval Units

HAEMATOLOGY - CBC MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE **BLOOD COUNTS, EDTA WHOLE BLOOD** 11.0 Low 12.0 - 15.0 g/dL HEMOGLOBIN (HB) METHOD: SLS-HEMOGLOBIN DETECTION METHOD RED BLOOD CELL (RBC) COUNT 3.83 3.8 - 4.8mil/μL METHOD: HYDRODYNAMIC FOCUSING BY DC DETECTION WHITE BLOOD CELL (WBC) COUNT 7.82 4.0 - 10.0thou/µL METHOD: FLUORESCENCE FLOW CYTOMETRY PLATELET COUNT 255 150 - 410 thou/µL METHOD: HYDRODYNAMIC FOCUSING BY DC DETECTION **RBC AND PLATELET INDICES** HEMATOCRIT (PCV) 35.2 Low 36.0 - 46.0 % METHOD: CUMULATIVE PULSE HEIGHT DETECTION METHOD MEAN CORPUSCULAR VOLUME (MCV) 83.0 - 101.0 fL 91.9 METHOD: CALCULATED FROM RBC & HCT MEAN CORPUSCULAR HEMOGLOBIN (MCH) 28.7 27.0 - 32.0 pg METHOD: CALCULATED FROM THE RBC & HGB 31.3 Low g/dL MEAN CORPUSCULAR HEMOGLOBIN 31.5 - 34.5 CONCENTRATION (MCHC) METHOD: CALCULATED FROM THE HGB & HCT RED CELL DISTRIBUTION WIDTH (RDW) 12.8 11.6 - 14.0 % METHOD: CALCULATED FROM RBC SIZE DISTRIBUTION CURVE 24.0 MENTZER INDEX 13.0 High fL MEAN PLATELET VOLUME (MPV) 6.8 - 10.9METHOD: CALCULATED FROM PLATELET COUNT & PLATELET HEMATOCRIT **WBC DIFFERENTIAL COUNT** NEUTROPHILS 56 40 - 80 % METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING 20 - 40 % LYMPHOCYTES 32 METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING MONOCYTES 6 2 - 10 % METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING **EOSINOPHILS** 6 1 - 6 % METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING % BASOPHILS 0 0 - 1 METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING ABSOLUTE NEUTROPHIL COUNT 4.38 2.0 - 7.0thou/µL



Page 5 Of 20

Dr.Priyal Chinchkhede Consultant Pathologist





View Details

View Repor

PERFORMED AT:



PATIENT NAME: NEHA GUPTA REF. DOCTOR: SELF CODE/NAME & ADDRESS : C000138394 ACCESSION NO: 0181WD000456 AGE/SEX :31 Years Female ACROFEMI HEALTHCARE LTD (MEDIWHEEL) PATIENT ID DRAWN : NEHAF091291181 F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 08/04/2023 08:15:06 DELHÍ ABHA NO REPORTED :12/04/2023 14:48:38 **NEW DELHI 110030** 8800465156

i i	j	
Results	Biological Reference	Interval Units
2.47	1.0 - 3.0	thou/µL
0.48	0.2 - 1.0	thou/µL
0.46	0.02 - 0.50	thou/µL
0.00 Low	0.02 - 0.10	thou/µL
1.8		
NORMOCYTIC NOR	MOCHROMIC	
NORMAL MORPHOL	.OG Y	
	2.47 0.48 0.46 0.00 Low 1.8 NORMOCYTIC NOR	2.47

PLATELETS ADEQUATE

Interpretation(s)
BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13)

from Beta thalassaemia trait

(< 13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for

diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. 3.3, COVID-19 patients tend to show mild disease.
(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504

This ratio element is a calculated parameter and out of NABL scope.

Bhindhehede

Dr.Priyal Chinchkhede Consultant Pathologist





Page 6 Of 20

PERFORMED AT:



PATIENT NAME: NEHA GUPTA REF. DOCTOR: SELF CODE/NAME & ADDRESS: C000138394 ACCESSION NO: 0181WD000456 AGE/SEX :31 Years Female ACROFEMI HEALTHCARE LTD (MEDIWHEEL) DRAWN PATIENT ID : NEHAF091291181 F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST RECEIVED : 08/04/2023 08:15:06 CLIENT PATIENT ID: DELHÍ REPORTED :12/04/2023 14:48:38 ABHA NO **NEW DELHI 110030** 8800465156

Test Report Status Results **Biological Reference Interval** Units Final

HAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD

E.S.R 21 High < 20 mm at 1 hr

METHOD: MODIFIED WESTERGREN

Interpretation(s)

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION:

Erythrocyte sedim entation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays' fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias,

Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).
In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc.), Hypercholesterolemia
False Decreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine,

salicylates)

1. Nathan and Oski's Haem atology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition.



Dr.Priyal Chinchkhede Consultant Pathologist





Page 7 Of 20

PERFORMED AT:



PATIENT NAME: NEHA GUPTA REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000138394 ACCESSION NO: 0181WD000456 AGE/SEX :31 Years Female

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) PATIENT ID DRAWN : NEHAF091291181

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 08/04/2023 08:15:06 DELHÍ ABHA NO REPORTED :12/04/2023 14:48:38 **NEW DELHI 110030**

Test Report Status Results Biological Reference Interval Units <u>Final</u>

IMMUNOHAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

TYPE B **ABO GROUP**

METHOD: GEL COLUMN AGGLUTINATION METHOD.

RH TYPE **POSITIVE**

METHOD: GEL COLUMN AGGLUTINATION METHOD.

Interpretation(s)

8800465156

ABO GROUP & RH TYPE, EDTA WHOLE BLOODBlood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.

The test is performed by both forward as well as reverse grouping methods.

@hindrede

Dr.Priyal Chinchkhede Consultant Pathologist Dr. Ushma Wartikar Consultant Pathologist

Page 8 Of 20







PATIENT NAME: NEHA GUPTA REF. DOCTOR: SELF

 CODE/NAME & ADDRESS : C000138394
 ACCESSION NO : 0181WD000456
 AGE/SEX : 31 Years
 Female

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) PATIENT ID : NEHAF091291181 DRAWN :

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

CLIENT PATIENT ID: RECEIVED :08/04/2023 08:15:06

NEW DELHI 110030 ABHA NO : REPORTED :12/04/2023 14:48:38

8800465156

Test Report Status Final Results Biological Reference Interval Units

BIOCHEMISTRY


MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

GLUCOSE FASTING, FLUORIDE PLASMA

FBS (FASTING BLOOD SUGAR) 86 Normal 75 - 99 mg/dL

Pre-diabetics: 100 - 125 Diabetic: > or = 126

METHOD: ENZYMATIC REFERENCE METHOD WITH HEXOKINASE



GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD

HBA1C 5.3 Non-diabetic Adult < 5.7 %

Pre-diabetes 5.7 - 6.4

Diabetes diagnosis: > or = 6.5

Therapeutic goals: < 7.0 Action suggested: > 8.0 (ADA Guideline 2021)

METHOD : HPLC

ESTIMATED AVERAGE GLUCOSE(EAG) 105.4 < 116.0 mg/dL

 ${\tt METHOD}: {\tt CALCULATED} \ {\tt PARAMETER}$

GLUCOSE, POST-PRANDIAL, PLASMA

Dr. Ushma Wartikar Consultant Pathologist Phinchkhede.

Dr.Priyal Chinchkhede Consultant Pathologist Augini

Dr.(Mrs)Neelu K Bhojani Lab Head





Page 9 Of 20

View Details

View Report

PERFORMED AT:

SRL Ltd Mulund Goregoan Link Road MUMBAI, 400078 MAHARASHTRA, INDIA Fax :

Fax : CIN - U74899PB1995PLC045956



PATIENT NAME: NEHA GUPTA REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000138394 ACCESSION NO: 0181WD000456 AGE/SEX :31 Years Female ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHÍ

NEW DELHI 110030 8800465156

PATIENT ID : NEHAF091291181

CLIENT PATIENT ID: ABHA NO

DRAWN

RECEIVED : 08/04/2023 08:15:06 REPORTED :12/04/2023 14:48:38

Test Report Status Results Biological Reference Interval <u>Final</u> Units


77

PPBS(POST PRANDIAL BLOOD SUGAR)

METHOD: ENZYMATIC REFERENCE METHOD WITH HEXOKINASE

70 - 139

mg/dL



LIPID PROFILE, SERUM

CHOLESTEROL, TOTAL mg/dL 141 Desirable: < 200

Borderline: 200 - 239

High: > / = 240

57 mg/dL TRIGLYCERIDES Normal: < 150

Borderline high: 150 - 199

High: 200 - 499

Very High: >/= 500

mg/dL HDL CHOLESTEROL 55 At Risk: < 40

Desirable: > or = 60

METHOD: ENZYMATIC, COLORIMETRIC

METHOD: ENZYMATIC COLORIMETRIC ASSAY

METHOD: ENZYMATIC COLORIMETRIC ASSAY

Dr. Ushma Wartikan Consultant Pathologist Bhinchkhede

Dr.Priyal Chinchkhede Consultant Pathologist Dr.(Mrs)Neelu K Bhojani Lab Head





Page 10 Of 20



PATIENT NAME: NEHA GUPTA REF. DOCTOR: SELF CODE/NAME & ADDRESS: C000138394 ACCESSION NO: 0181WD000456 AGE/SEX :31 Years Female ACROFEMI HEALTHCARE LTD (MEDIWHEEL) PATIENT ID : NEHAF091291181 DRAWN F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 08/04/2023 08:15:06 DELHÍ ABHA NO REPORTED :12/04/2023 14:48:38 **NEW DELHI 110030** 8800465156

Test Report Status <u>Final</u>	Results	Biological Reference Interva	l Units
CHOLESTEROL LDL	75	Adult levels: Optimal < 100 Near optimal/above optimal 100-129 Borderline high: 130-159 High: 160-189 Very high: = 190	mg/dL :
METHOD: ENZYMATIC COLORIMETRIC ASSAY NON HDL CHOLESTEROL	86	Desirable : < 130 Above Desirable : 130 -159 Borderline High : 160 - 189 High : 190 - 219 Very high : > / = 220	mg/dL
VERY LOW DENSITY LIPOPROTEIN	11.4	< OR = 30.0	mg/dL
CHOL/HDL RATIO	2.6 Low	Low Risk: 3.3 - 4.4 Average Risk: 4.5 - 7.0 Moderate Risk: 7.1 - 11.0 High Risk: > 11.0	
LDL/HDL RATIO	1.4	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Modera Risk >6.0 High Risk	
Interpretation(s)			
LIVER FUNCTION PROFILE, SERUM			
BILIRUBIN, TOTAL METHOD: COLORIMETRIC DIAZO	0.24	Upto 1.2	mg/dL
BILIRUBIN, DIRECT	0.14	< 0.30	mg/dL
BILIRUBIN, INDIRECT	0.10	0.1 - 1.0	mg/dL
TOTAL PROTEIN	6.4	6.0 - 8.0	g/dL
METHOD: COLORIMETRIC			
ALBUMIN METHOD: COLORIMETRIC	4.3	3.97 - 4.94	g/dL
GLOBULIN	2.1	2.0 - 3.5	g/dL
ALBUMIN/GLOBULIN RATIO	2.1	1.0 - 2.1	RATIO
ASPARTATE AMINOTRANSFERASE(AST/SGOT) METHOD: UV ABSORBANCE	26	< OR = 35	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT)	28	< OR = 35	U/L

Dr. Ushma Wartikar Consultant Pathologist Phindrede.

Dr.Priyal Chinchkhede Consultant Pathologist Angone

Dr.(Mrs)Neelu K Bhojani Lab Head



Page 11 Of 20

View Details







PATIENT NAME: NEHA GUPTA REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000138394 ACCESSION NO: 0181WD000456 AGE/SEX :31 Years Female ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHÍ

NEW DELHI 110030

METHOD: ENZYMATIC ASSAY

8800465156


PATIENT ID : NEHAF091291181

CLIENT PATIENT ID: ABHA NO

DRAWN

RECEIVED : 08/04/2023 08:15:06 REPORTED :12/04/2023 14:48:38

	į		
Test Report Status <u>Final</u>	Results	Biological Referenc	e Interval Units
METHOD: UV ABSORBANCE	113 High	2E 104	1171
ALKALINE PHOSPHATASE METHOD: COLORIMETRIC	II3 nigii	35 - 104	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT)	7	0 - 40	U/L
METHOD : ENZYMATIC, COLORIMETRIC	•	0 40	0,12
LACTATE DEHYDROGENASE	164	125 - 220	U/L
METHOD: UV ABSORBANCE			
BLOOD UREA NITROGEN (BUN), SERUM			
` "	_		
BLOOD UREA NITROGEN	9	6 - 20	mg/dL



METHOD : COLORIMETRIC

Dr. Ushma Wartikar Consultant Pathologist Bhinchkhede

Dr.Priyal Chinchkhede Consultant Pathologist

Dr.(Mrs)Neelu K Bhojani Lab Head




mg/dL



Page 12 Of 20








PATIENT NAME: NEHA GUPTA REF. DOCTOR: SELF CODE/NAME & ADDRESS: C000138394 ACCESSION NO: 0181WD000456 AGE/SEX :31 Years Female ACROFEMI HEALTHCARE LTD (MEDIWHEEL) PATIENT ID : NEHAF091291181 DRAWN F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 08/04/2023 08:15:06 DELHÍ ABHA NO REPORTED :12/04/2023 14:48:38 **NEW DELHI 110030** 8800465156

Test Report Status Biological Reference Interval Results Units <u>Final</u>



Dr. Ushma Wartikar Consultant Pathologist @hindrede

Dr.Priyal Chinchkhede Consultant Pathologist

Dr.(Mrs)Neelu K Bhojani Lab Head





Page 13 Of 20



SRL Ltd Mulund Goregoan Link Road MUMBAI, 400078 MAHARÁSHTRA, INDIA CIN - U74899PB 1995PLC045956



PATIENT NAME: NEHA GUPTA REF. DOCTOR: SELF CODE/NAME & ADDRESS: C000138394 ACCESSION NO: 0181WD000456 AGE/SEX :31 Years Female ACROFEMI HEALTHCARE LTD (MEDIWHEEL) DRAWN PATIENT ID : NEHAF091291181 F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 08/04/2023 08:15:06 DELHÍ ABHA NO REPORTED :12/04/2023 14:48:38 **NEW DELHI 110030** 8800465156

Biological Reference Interval Test Report Status Results Units <u>Final</u>

POTASSIUM, SERUM 4.52 3.5 - 5.1mmol/L CHLORIDE, SERUM 103 98 - 107 mmol/L

Interpretation(s)

Sodium	Potassium	Chloride		
Decreased in: CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, antidepressants (SSRI), antipsychotics.	Decreased in: Low potassium intake, prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome, osmotic diuresis (e.g., hyperglycemia), alkalosis, familial periodic paralysis, trauma (transient). Drugs: Adrenergic agents, diuretics.	Decreased in: Vamiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis, diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenalinsufficiency, hyperaldosterorism, metabolic alkalosis. Drugs: chronic laxative, corticosteroids, diuretics.		
Increased in: Dehydration (excessivesweating, severe vomiting or diarrhea), diabetes mcIlitus, diabetesinsipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice, oral contraceptives.	Increased in: Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration, renal failure, Addison's disease, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium sparing diuretics, NSAIDs, beta-blockers, ACE inhibitors, highdose trimethoprim-sulfamethoxazole.	Increased in: Renal failure, nephrotic syndrome, RTA, dehydration, overtreatment with saline, hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO3-), respiratory alkalosis, hyperadrenocorticism. Drugs: acetazolamide, androgens, hydrochlorothiazide, salicylates.		
Interferences: Severe lipemia or hyperproteinemi, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.	Interferences: Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal.	Interferences: Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride)		

Interpretation(s)

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the

Increased in:Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs: corticosteroids, phenytoin, estrogen, thiazides. Decreased in:Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease,

malignancy(adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency diseases(e.g.galactosemia),Drugs-insulin,ethanol,propranolol;sulfonylureas,tolbutamide,and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals.Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-**Used For:**

- 1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- 2. Diagnosing diabetes.

3. Identifying patients at increased risk for diabetes (prediabetes).
The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

Dr. Ushma Wartikar Consultant Pathologist Bhinchkhede

Dr.Priyal Chinchkhede Consultant Pathologist

Dr.(Mrs)Neelu K Bhojani Lab Head





Page 14 Of 20

PERFORMED AT:



PATIENT NAME: NEHA GUPTA REF. DOCTOR: SELF CODE/NAME & ADDRESS: C000138394 ACCESSION NO : 0181WD000456 AGE/SEX :31 Years Female ACROFEMI HEALTHCARE LTD (MEDIWHEEL) PATIENT ID : NEHAF091291181 DRAWN F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST RECEIVED : 08/04/2023 08:15:06 CLIENT PATIENT ID: DELHÍ ABHA NO REPORTED :12/04/2023 14:48:38 **NEW DELHI 110030** 8800465156

Test Report Status Results Biological Reference Interval Units <u>Final</u>

- 1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.
- eAG gives an evaluation of blood glucose levels for the last couple of months.
 eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c 46.7

HbA1c Estimation can get affected due to :

- 1. Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss,hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.
- 2. Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.
- 3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods falsely increasing results.
- 4. Interference of hemoglobinopathies in HbA1c estimation is seen in
- a) Homozygous hemoglobinopathy, Fructosamine is recommended for testing of HbA1c.
- b) Heterozygous state detected (010 is corrected for HbS & HbC trait.)
 b) Heterozygous state detected (010 is corrected for HbS & HbC trait.)
 c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a vellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health. AST levels increase during acute hepatitis, sometimes due to a viral infection, is chemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.Lower-than-normal levels may be due to: Agammaglobulinemia,Bleeding (hemorrhage),Burns,Glomerulonephritis,Liver disease, Malabsorption,Malnutrition,Nephrotic syndrome,Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc

BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM-Higher than normal level may be due to:

• Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to: Myasthenia Gravis, Muscuophy

URIC ACID, SERUM-Causes of Increased levels: Dietary(High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic syndrome Causes of decreased levels: Low Zinc intake, OCP, Multiple Sclerosis

TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.

Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome,Protein-losing enteropathy etc. ALBUMIN, SERUM-

Hum an sérum albumin is the most abundant protein in hum an blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

Dr. Ushma Wartikar Consultant Pathologist Bhinchkhede

Dr.Priyal Chinchkhede Consultant Pathologist

Dr.(Mrs)Neelu K Bhojani Lab Head





Page 15 Of 20



PERFORMED AT:

SRL Ltd Mulund Goregoan Link Road MUMBAI, 400078 MAHARÁSHTRA, INDIA CIN - U74899PB1995PLC045956



PATIENT NAME: NEHA GUPTA REF. DOCTOR: SELF

CODE/NAME & ADDRESS : C000138394 ACCESSION NO : **0181WD000456** AGE/SEX : **31 Years** Female

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST

F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI

NEW DELHI 110030

8800465156

Accession no : 01011110000450

PATIENT ID : NEHAF091291181

CLIENT PATIENT ID: ABHA NO : DRAWN :

1 :

RECEIVED :08/04/2023 08:15:06 REPORTED :12/04/2023 14:48:38

Test Report Status <u>Final</u> Results Biological Reference Interval Units

CLINICAL PATH - URINALYSIS

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

PHYSICAL EXAMINATION, URINE

COLOR YELLOWISH APPEARANCE CLEAR

CHEMICAL EXAMINATION, URINE

PH 6.0 5.00 - 7.50 SPECIFIC GRAVITY 1.020 1.010 - 1.030

METHOD: URINE ROUTINE & MICROSCOPY EXAMINATION BY INTEGRATED AUTOMATED SYSTEM

PROTEIN NOT DETECTED NOT DETECTED
GLUCOSE NOT DETECTED NOT DETECTED
KETONES NOT DETECTED NOT DETECTED
BLOOD NOT DETECTED NOT DETECTED

UROBILINOGEN NORMAL NORMAL

NITRITE NOT DETECTED NOT DETECTED

LEUKOCYTE ESTERASE NOT DETECTED NOT DETECTED

MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS

NOT DETECTED

NOT DETECTED

/HPF

PUS CELL (WBC'S)

3-5

C-5

/HPF

EPITHELIAL CELLS

1-2

O-5

/HPF

CASTS NOT DETECTED
CRYSTALS NOT DETECTED

BACTERIA NOT DETECTED NOT DETECTED
YEAST NOT DETECTED NOT DETECTED

METHOD: URINE ROUTINE & MICROSCOPY EXAMINATION BY INTEGRATED AUTOMATED SYSTEM

Interpretation(s)

Bhinchkhede.

Dr.Priyal Chinchkhede Consultant Pathologist Dr. Ushma Wartikar Consultant Pathologist

Dr.(Mrs)Neelu K Bhojani Lab Head



Page 16 Of 20

View Details

View Report



PATIENT NAME: NEHA GUPTA REF. DOCTOR: SELF CODE/NAME & ADDRESS: C000138394 ACCESSION NO: 0181WD000456 AGE/SEX :31 Years Female ACROFEMI HEALTHCARE LTD (MEDIWHEEL) DRAWN PATIENT ID : NEHAF091291181 F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 08/04/2023 08:15:06 DELHÍ REPORTED :12/04/2023 14:48:38 ABHA NO **NEW DELHI 110030** 8800465156

Test Report Status Results Biological Reference Interval Units <u>Final</u>

CYTOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

PAPANICOLAOU SMEAR

CONVENTIONAL GYNEC CYTOLOGY TEST METHOD

METHOD: MICROSCOPIC EXAMINATION

P-526/23 SPECIMEN TYPE

TWO UNSTAINED CERVICAL SMEARS RECEIVED

METHOD: MICROSCOPIC EXAMINATION 2014 BETHESDA SYSTEM FOR REPORTING CERVICAL CYTOLOGY REPORTING SYSTEM

SPECIMEN ADEQUACY SATISFACTORY

METHOD: PAP STAIN & MICROSCOPIC EXAMINATION

MICROSCOPY THE SMEARS SHOW MAINLY SUPERFICIAL SQUAMOUS CELLS, FEW

INTERMEDIATE SQUAMOUS CELLS, MANY CLUSTERS OF ENDOCERVICAL

CELLS IN THE BACKGROUND OF FEW POLYMORPHS.

METHOD: PAP STAIN

NEGATIVE FOR INTRAEPITHELIAL LESION OR MALIGNANCY INTERPRETATION / RESULT

METHOD: PAP STAIN & MICROSCOPIC EXAMINATION

Comments

PLEASE NOTE PAPANI COLAU SMEAR STUDY IS A SCREENING PROCEDURE FOR CERVICAL CANCER WITH INHERENT FALSE NEGATIVE RESULTS HENCE SHOULD BE INTERPRETED WITH CAUTION. NO CYTOLOGICAL EVIDENCE OF HPV INFECTION IN THE SMEARS STUDIED. SMEARS WILL BE PRESERVED FOR 5 YEARS ONLY.



Dr.Priyal Chinchkhede Consultant Pathologist





Page 17 Of 20

PERFORMED AT:

CIN - U74899PB1995PLC045956



PATIENT NAME: NEHA GUPTA REF. DOCTOR: SELF CODE/NAME & ADDRESS: C000138394 ACCESSION NO: 0181WD000456 AGE/SEX :31 Years Female ACROFEMI HEALTHCARE LTD (MEDIWHEEL) PATIENT ID DRAWN : NEHAF091291181 F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 08/04/2023 08:15:06 DELHÍ ABHA NO REPORTED :12/04/2023 14:48:38 **NEW DELHI 110030** 8800465156

Test Report Status <u>Final</u> Results Biological Reference Interval Units

CLINICAL PATH - STOOL ANALYSIS

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

PHYSICAL EXAMINATION, STOOL

COLOUR DARK BROWN

METHOD : VISUAL

CONSISTENCY SEMI FORMED

METHOD : VISUAL

MUCUS NOT DETECTED NOT DETECTED

METHOD: VISUAL

VISIBLE BLOOD ABSENT ABSENT ABSENT

METHOD: VISUAL

CHEMICAL EXAMINATION, STOOL

OCCULT BLOOD NOT DETECTED NOT DETECTED

METHOD : HEMOSPOT

MICROSCOPIC EXAMINATION, STOOL

PUS CELLS 2-3 /hpf

RED BLOOD CELLS NOT DETECTED NOT DETECTED /HPF

METHOD: MICROSCOPIC EXAMINATION

CYSTS NOT DETECTED NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

OVA

NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

LARVAE NOT DETECTED NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

TROPHOZOITES NOT DETECTED NOT DETECTED

FAT ABSENT
VEGETABLE CELLS PRESENT

CONCENTRATION METHOD NO OVA CYST SEEN AFTER PERFORMING CONCENTRATION TECHNIQUE

FOR STOOL SAMPLE

Interpretation(s)

METHOD: MICROSCOPIC EXAMINATION

Dr. Sheetal Sawant Consultant Microbiologist





Page 18 Of 20

View Details

May Doport

PERFORMED AT:



REF. DOCTOR: SELF **PATIENT NAME: NEHA GUPTA** CODE/NAME & ADDRESS: C000138394 ACCESSION NO : 0181WD000456 AGE/SEX :31 Years Female ACROFEMI HEALTHCARE LTD (MEDIWHEEL) DRAWN PATIENT ID : NEHAF091291181 F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 08/04/2023 08:15:06 DELHÍ ABHA NO REPORTED :12/04/2023 14:48:38 **NEW DELHI 110030** 8800465156

Test Report Status Final Results Biological Reference Interval Units

SPECIALISED CHEMISTRY - HORMONE

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

THYROID PANEL, SERUM

T3 107.0 Non-Pregnant Women ng/dL

80.0 - 200.0 Pregnant Women

1st Trimester:105.0 - 230.0 2nd Trimester:129.0 - 262.0 3rd Trimester:135.0 - 262.0

METHOD: ELECTROCHEMILUMINESCENCE

T4 7.49 Non-Pregnant Women μg/dL

5.10 - 14.10 Pregnant Women

1st Trimester: 7.33 - 14.80 2nd Trimester: 7.93 - 16.10 3rd Trimester: 6.95 - 15.70

METHOD : ELECTROCHEMILUMINESCENCE

TSH (ULTRASENSITIVE) 1.610 Non Pregnant Women µIU/mL

0.27 - 4.20

Pregnant Women

1st Trimester: 0.33 - 4.59 2nd Trimester: 0.35 - 4.10 3rd Trimester: 0.21 - 3.15

METHOD: ELECTROCHEMILUMINESCENCE

Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. owidetlparowidetlparBelow mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3 Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
					Post Thyroidectomy (4) Post Radio-Iodine treatment

Dr. Ushma Wartikar Consultant Pathologist Phindhenede.

Dr.Priyal Chinchkhede Consultant Pathologist Bhajan

Dr.(Mrs)Neelu K Bhojani Lab Head





Page 19 Of 20

View Details

View Report

PERFORMED AT:



PATIENT NAME: NEHA GUPTA REF. DOCTOR: SELF CODE/NAME & ADDRESS: C000138394 ACCESSION NO: 0181WD000456 AGE/SEX :31 Years Female ACROFEMI HEALTHCARE LTD (MEDIWHEEL) PATIENT ID : NEHAF091291181 DRAWN F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 08/04/2023 08:15:06 DELHÍ REPORTED :12/04/2023 14:48:38 ABHA NO **NEW DELHI 110030** 8800465156

Test Report Status Final Results Biological Reference Interval Units

2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid hormone replacement therapy (3) In cases of Autoimmune/Hashimoto thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical inflammation, drugs like amphetamines, Iodine containing drug and dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre (3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4 replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2.Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. NOTE: It is advisable to detect Free T3,FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4,TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

Dr. Ushma Wartikar Consultant Pathologist Bhindrede.

Dr.Priyal Chinchkhede Consultant Pathologist Dr.(Mrs)Neelu K Bhojani Lab Head Page 20 Of 20





View Details

View Report

